Feeds › 8-K events
8-K events
Major news companies must report to the SEC: results, deals, leadership changes.
About this data
- What it is
- A Form 8-K is how a public company announces major news between its quarterly reports: earnings, an acquisition, a new CEO, a cybersecurity incident. Each filing lists the numbered items it covers.
- Who files it
- The company, usually within four business days of the event.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Many 8-Ks are routine, so the item description is the place to start. Item 9.01, which only lists attached documents, is hidden unless you ask for it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
8-K items filed per day, last 30 days
All items Earnings results (2.02)
One filing can report several items. Item 9.01, which only lists attached documents, is not counted.
Latest 8-K filings
Showing: ticker BBOT
| Filed | Company | Item | Form | Filing |
|---|---|---|---|---|
| Nov 10, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Nov 5, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Sep 8, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Aug 11, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jun 22, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Jun 22, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| May 12, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Apr 29, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Apr 23, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Apr 23, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Mar 26, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Mar 5, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Jan 7, 2026 | BBOT BridgeBio Oncology Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Nov 12, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 2.02 Results of Operations and Financial Condition | 8-K | 8-K ↗ |
| Aug 13, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 8.01 Other Events | 8-K | 8-K ↗ |
| Aug 13, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Aug 13, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 5.06 Change in Shell Company Status | 8-K | 8-K ↗ |
| Aug 13, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 5.05 Amendments to the Code of Ethics, or Waiver of a Provision | 8-K | 8-K ↗ |
| Aug 13, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K | 8-K ↗ |
| Aug 13, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
| Aug 13, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 5.01 Changes in Control of Registrant | 8-K | 8-K ↗ |
| Aug 13, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 4.01 Changes in Registrant's Certifying Accountant | 8-K | 8-K ↗ |
| Aug 13, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 3.03 Material Modification to Rights of Security Holders | 8-K | 8-K ↗ |
| Aug 13, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Aug 13, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 2.01 Completion of Acquisition or Disposition of Assets | 8-K | 8-K ↗ |
| Aug 13, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Aug 6, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Aug 4, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 5.07 Submission of Matters to a Vote of Security Holders | 8-K | 8-K ↗ |
| Jul 11, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Mar 3, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 3.02 Unregistered Sales of Equity Securities | 8-K | 8-K ↗ |
| Mar 3, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 1.01 Entry into a Material Definitive Agreement | 8-K | 8-K ↗ |
| Feb 28, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 7.01 Regulation FD Disclosure | 8-K | 8-K ↗ |
| Feb 10, 2025 | BBOT BridgeBio Oncology Therapeutics, Inc. | 5.02 Departure or Election of Directors or Officers; Compensatory Arrangements | 8-K | 8-K ↗ |
33 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 5:28 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances